
26-week randomized treatment period
Prespecified iGlarLixi 26-week extension period
Key eligibility criteria
• Type 2 diabetes ≥1 year
• HbA1c 7–9 % (53–75 mmol/mol)
• Liraglutide once daily, or exenatide twice daily for ≥4 months
• Exenatide ER, albiglutide, or dulaglutide once weekly for ≥6 months
• + metformin ± pioglitazone ± SGLT2 inhibitor
R 1:1
Continue previous GLP-1 RA
+ metformin ± pioglitazone ± SGLT2 inhibitor
iGlarLixi
Inclusion criteria for extension period
• No rescue therapy
OR
• Rescue therapy but HbA1c ≤8 % (64 mmol/mol) at week 22
AND
• No premature discontinuation of iGlarLixi treatment before week 26
iGlarLixi extension
Time of primary endpoint measurement